Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 7.78B +19.4% |
| Revenue (ttm) | 280.75M +61.0% |
| Net Income | -198.30M |
| EPS | -2.91 |
| Shares Out | 69.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 734,103 |
| Open | 113.76 |
| Previous Close | 113.95 |
| Day's Range | 112.04 - 115.20 |
| 52-Week Range | 74.50 - 122.20 |
| Beta | 2.14 |
| Analysts | Strong Buy |
| Price Target | 140.12 (+24.93%) |
| Earnings Date | Nov 3, 2026 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic... [Read more]
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price target is $140.12, which is an increase of 24.93% from the latest price.
News
Rhythm Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026
The U.S. AHO launch has generated more than 700 start forms, with Japan treatment underway and additional ex-U.S. launches expected in 2027. Bivamelagon PWS trials are planned for 2027, alongside higher development and launch spending.
Rhythm Pharmaceuticals management to meet with Citizens
Meeting to be held in National Habor, MD on November 15 hosted by Citizens.
Rhythm Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Management cited steady HO launch progress through Q4 and a 10,000-patient prevalence estimate, with further growth possible as diagnosis improves. Pipeline plans include initiating HO and PWS trials and presenting 52-week PWS data, hopefully early in spring.
Rhythm Pharmaceuticals takeover rumor highlighted in Betaville blog
A post in Ben Harrington’s deal-focused Betaville blog discusses rumors that Rhythm Pharmaceuticals (RYTM) is working with Goldman Sachs (GS) and that there are multiple bidders seeking a deal for…
Rhythm Pharmaceuticals price target lowered to $142 from $145 at JPMorgan
JPMorgan analyst Priyanka Grover lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $142 from $145 and keeps an Overweight rating on the shares.
Rhythm Pharmaceuticals price target raised to $147 from $143 at Guggenheim
Guggenheim raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $147 from $143 and keeps a Buy rating on the shares.
Rhythm Pharmaceuticals price target raised to $168 from $154 at Canaccord
Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $168 from $154 and keeps a Buy rating on the shares. The firm said they reported 3Q26 earnings, with…
Rhythm Pharmaceuticals trading resumes
16:00 EST Rhythm Pharmaceuticals (RYTM) trading resumes
AstraZeneca recently made $10B offer to buy Rhythm Pharmaceuticals, WSJ says
AstraZeneca (AZN) recently made a roughly $10B offer to acquire Rhythm Pharmaceuticals (RYTM) for $124 per share, according to people familiar with the matter, The Wall Street Journal’s Lauren Thomas…
Rhythm Pharmaceuticals trading halted, volatility trading pause
15:57 EST Rhythm Pharmaceuticals (RYTM) trading halted, volatility trading pause
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
Rhythm Pharmaceuticals price target lowered to $146 from $150 at Morgan Stanley
Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $146 from $150 and keeps an Overweight rating on the shares.
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals...
Rhythm Pharmaceuticals price target raised to $166 from $160 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $166 from $160 and keeps an Outperform rating on the shares. Rhythm’s setup is viewed favorably,…
Rhythm Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 sales reached $92.1M, driven by U.S. acquired HO demand, while Japan launched and European access advanced. Bivamelagon Phase III plans and a royalty buy-down were backed by new term financing.
Rhythm Pharmaceuticals Earnings release: Q3 2026
Rhythm Pharmaceuticals released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Rhythm Pharmaceuticals Slides: Q3 2026
Rhythm Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Rhythm Pharmaceuticals Quarterly report: Q3 2026
Rhythm Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 3, 2026.
Rhythm Pharmaceuticals reports Q3 EPS (61c), consensus (74c)
Reports Q3 revenue $92.13M, consensus $84.6M. “Rhythm continues to make strong progress in bringing IMCIVREE to patients with acquired hypothalamic obesity, highlighted by continued commercial momentu...
Rhythm Pharmaceuticals sees FY26 operating expenses $360M-$380M
Meeker added, “We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple ind...
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 ...
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem addi...
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals initiated with an Outperform at William Blair
William Blair analyst Alethia Young initiated coverage of Rhythm Pharmaceuticals (RYTM) with an Outperform rating. Rhythm is a global, commercial-stage rare neuroendocrine name with an approved drug c...
JPMorgan trims Rhythm Pharmaceuticals target, adds to Analyst Focus List
JPMorgan analyst Priyanka Grover lowered the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $145 from $146 and keeps an Overweight rating on the shares. JPMorgan also added Rhythm to…